LINCOLNPharmaceuticals
Lincoln Pharmaceuticals Ltd — PE Ratio & Valuation Analysis
₹564.95
-2.30%
Current P/E12.68xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E13.9x8.9% below avg
✅
60.1% Discount to Industry
LINCOLN P/E 12.68x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹41.11 | ₹484 | 11.8x |
| 2024 | ₹46.58 | ₹788 | 16.9x |
| 2023 | ₹36.40 | ₹610 | 16.7x |
| 2022 | ₹34.63 | ₹356 | 10.3x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Lincoln Pharmaceuticals Ltd Valuation
Lincoln Pharmaceuticals Ltd (LINCOLN) currently trades at 12.68x earnings. The Pharmaceuticals sector average PE is 31.77x. LINCOLN is trading at a discount to peers — may indicate relative value. Historically, LINCOLN has traded at an average PE of 13.9x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
12.82%
Dividend Yield
0.36%
More on Lincoln Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.